Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

InMed Pharmaceuticals (INM) EBIT Margin (2021 - 2025)

InMed Pharmaceuticals' EBIT Margin history spans 5 years, with the latest figure at 256.36% for Q4 2025.

  • For Q4 2025, EBIT Margin fell 5360.0% year-over-year to 256.36%; the TTM value through Dec 2025 reached 174.87%, down 1205.0%, while the annual FY2025 figure was 160.77%, 1750.0% up from the prior year.
  • EBIT Margin reached 256.36% in Q4 2025 per INM's latest filing, down from 162.54% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 20.99% in Q2 2023 to a low of 1626.64% in Q4 2021.
  • Average EBIT Margin over 5 years is 450.84%, with a median of 202.75% recorded in 2024.
  • Peak YoY movement for EBIT Margin: surged 124562bps in 2023, then crashed -13755bps in 2024.
  • A 5-year view of EBIT Margin shows it stood at 1626.64% in 2021, then soared by 71bps to 471.26% in 2022, then soared by 72bps to 132.64% in 2023, then plummeted by -53bps to 202.75% in 2024, then decreased by -26bps to 256.36% in 2025.
  • Per Business Quant, the three most recent readings for INM's EBIT Margin are 256.36% (Q4 2025), 162.54% (Q3 2025), and 139.49% (Q2 2025).